Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.

Bioorg Med Chem Lett 2019 Jun 4;29(12):1522-1531. Epub 2019 Apr 4.

Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.

Disruption of interleukin-13 (IL-13) signaling with large molecule antibody therapies has shown promise in diseases of allergic inflammation. Given that IL-13 recruits several members of the Janus Kinase family (JAK1, JAK2, and TYK2) to its receptor complex, JAK inhibition may offer an alternate small molecule approach to disrupting IL-13 signaling. Herein we demonstrate that JAK1 is likely the isoform most important to IL-13 signaling. Structure-based design was then used to improve the JAK1 potency of a series of previously reported JAK2 inhibitors. The ability to impede IL-13 signaling was thereby significantly improved, with the best compounds exhibiting single digit nM IC's in cell-based assays dependent upon IL-13 signaling. Appropriate substitution was further found to influence inhibition of a key off-target, LRRK2. Finally, the most potent compounds were found to be metabolically labile, which makes them ideal scaffolds for further development as topical agents for IL-13 mediated diseases of the lungs and skin (for example asthma and atopic dermatitis, respectively).

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2019.04.008DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
June 2019
3 Reads

Publication Analysis

Top Keywords

il-13 signaling
24
il-13
8
janus kinase
8
signaling
6
inhibitors ability
4
exhibiting single
4
jak2 inhibitors
4
reported jak2
4
potency series
4
series reported
4
ability impede
4
compounds exhibiting
4
signaling improved
4
improved best
4
impede il-13
4
jak1 potency
4
single digit
4
best compounds
4
improve jak1
4
alternate small
4

Similar Publications